Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs

Core Insights - Caribou Biosciences is strategically prioritizing its lead oncology programs, CB-010 and CB-011, while implementing workforce and cost reduction initiatives to extend its cash runway into H2 2027 [1][13] - The company plans to disclose robust clinical datasets for CB-010 and CB-011 in H2 2025, which are expected to demonstrate efficacy in treating hematologic malignancies [2][14] Pipeline Prioritization - Caribou is focusing resources on CB-010 and CB-011, discontinuing the GALLOP Phase 1 trial for lupus and the AMpLify Phase 1 trial for acute myeloid leukemia [5][7] - The workforce reduction is approximately 32%, with expected cash savings of $2.5 to $3.5 million from these strategic decisions [13] Clinical Programs - CB-010 is an allogeneic anti-CD19 CAR-T cell therapy for B cell non-Hodgkin lymphoma, with data expected to show outcomes comparable to approved autologous CAR-T therapies [6][10] - CB-011 is an allogeneic anti-BCMA CAR-T cell therapy for multiple myeloma, with ongoing dose escalation trials showing encouraging efficacy [4][11] Financial Position - As of March 31, 2025, Caribou expects to report $212.5 million in cash, cash equivalents, and marketable securities [8] - The strategic changes are anticipated to extend the company's cash runway by one year, allowing operations to continue into H2 2027 [13] Upcoming Milestones - In H2 2025, Caribou plans to present data from the ANTLER Phase 1 trial for CB-010, including safety and efficacy data from a 20-patient cohort [14] - For CB-011, the company will present dose escalation data and recommended doses for expansion from the ongoing CaMMouflage Phase 1 trial [14]